Characterization of Synthesized Ramucirumab-vcMMAE as a Potential Therapeutic Approach in Ovarian Cancer

Area of Science:

• Oncology
• Bioconjugation Chemistry
• Pharmacology

Background:

• Ovarian cancer often presents at late stages, necessitating advanced treatment strategies.
• Current chemotherapy faces challenges including side effects and drug resistance.
• Targeted drug delivery systems are crucial for improving treatment selectivity and efficacy.

Purpose of the Study:

• To synthesize and evaluate an Antibody-Drug Conjugate (ADC) for targeted ovarian cancer therapy.
• To assess the in vitro efficacy and safety of the novel ADC in ovarian cancer cell lines.
• To investigate the structural and functional characteristics of the synthesized conjugate.

Main Methods:

• Synthesis of Ramucirumab-mc-vc-PAB-MMAE (R-vcMMAE) via disulfide bond reduction and alkylation.
• Structural, physicochemical, and functional analyses of the synthesized ADC.
• In vitro efficacy testing on normal and ovarian cancer cell lines (primary and metastatic).

Main Results:

• The R-vcMMAE conjugate demonstrated a drug-to-antibody ratio of 3.2 with >95% monomeric protein content.
• Conjugation minimally impacted R-vcMMAE's binding affinity to ovarian cancer cells.
• R-vcMMAE inhibited 50% of ovarian cancer cell viability at ~6 nM, with no observed toxicity to normal ovarian cells.

Conclusions:

• The synthesized ADC (R-vcMMAE) is structurally sound and functionally effective.
• This targeted ADC exhibits high specificity and efficacy against ovarian cancer cells in vitro.
• The developed ADC presents a potentially safer and more effective therapeutic option for ovarian cancer treatment.